Recombinant Human CLEC4C Protein，His

CLEC4C, also known as DC-SIGNR, is a C-type lectin receptor primarily expressed in dendritic cells and macrophages, playing a pivotal role in the immune response. This receptor is known for its ability to bind to a variety of pathogens, including viruses and bacteria, facilitating their recognition and internalization by antigen-presenting cells. Research has indicated that CLEC4C can influence T-cell activation and polarize immune responses, making it a potential target for therapeutic strategies in infectious diseases, cancer, and autoimmune disorders. The study of CLEC4C recombinant proteins has gained significant interest as these proteins can serve as tools for understanding the receptor's structure-function relationships, its interactions with various ligands, and its role in immune modulation. By elucidating the mechanisms underlying CLEC4C interactions, researchers aim to develop novel immunotherapies and vaccines that enhance immune responses or attenuate undesirable inflammatory processes. Furthermore, as the landscape of infectious diseases evolves, understanding the specificity and efficacy of CLEC4C in recognizing emerging pathogens remains a critical area of investigation. The recombinant form of CLEC4C not only aids in basic research but also holds promise for clinical applications, offering a pathway to harness the immune system more effectively against various diseases. Overall, the exploration of CLEC4C recombinant proteins represents a significant step forward in immunology, with implications that extend from fundamental science to the development of innovative therapeutic approaches.